Determination of HER2 over-expression in breast carcinomas has become important in clinical practice, with the advent of anti-HER2 therapy as demonstrated in clinical trials [5–7], such as the BCIRG 006, NSABP B31/N9831 and HEAR trials. The gene discussed is ERBB2; the disease is breast carcinoma.